Current vascular pharmacology最新文献_第5页

Introducing the Concept of Hypertensive Heart Disease to Improve Hypertensive Left Ventricular Hypertrophy. 引入高血压性心脏病概念，改善高血压左室肥厚。

IF 2.1 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611351415241212092014

Goran Koracevic, Milovan Stojanovic, Marija Zdravkovic, Dragan Simic, Dragan Lovic, Dragan Djordjevic, Suzana Otasevic, Miloje Tomasevic, Dejan Sakac

{"title":"Introducing the Concept of Hypertensive Heart Disease to Improve Hypertensive Left Ventricular Hypertrophy.","authors":"Goran Koracevic, Milovan Stojanovic, Marija Zdravkovic, Dragan Simic, Dragan Lovic, Dragan Djordjevic, Suzana Otasevic, Miloje Tomasevic, Dejan Sakac","doi":"10.2174/0115701611351415241212092014","DOIUrl":"10.2174/0115701611351415241212092014","url":null,"abstract":"Background: Among the organ damage mediated by hypertension, cardiac lesions hold significant importance. Numerous authors focus on hypertensive heart disease (HHD) rather than exclusively on left ventricular hypertrophy (LVH).Objectives: This narrative review aims to assess the incorporation of the concept of 'hypertensive heart disease' (HHD) in hypertension (HTN) guidelines. Furthermore, if HHD is not addressed, the review will evaluate the potential benefits of including this concept in future studies.Methods: The following databases were searched: Scopus, Medline, Springer, Science Direct, Wiley, SAGE, Cambridge, Oxford Journals, and Google Scholar. Attention was given to the guidelines related to hypertension (HTN); the search items were \"guidelines\" and \"hypertension.\" Within these guidelines, we specifically sought references to 'hypertensive heart disease.'.Results: The concept of \"HHD\" is clearly advantageous compared to \"HTN LVH,\" as it not only addresses LVH but also considers other structures of the heart that may be severely affected, which can significantly influence treatment. The concept of \"hypertensive heart disease\" is mentioned in only 8 out of 36 guidelines on HTN. The therapeutic implications and recommendations are absent in the guidelines.Conclusion: The concept of HHD is reasonable and evidence-based, and there is no reason to focus only on LVH when considering HTN-induced damage to the heart. It is time to update our recommendations for heart treatment by using the phrase \"Treatment of hypertensive heart disease\" instead of \"Treatment of hypertensive LVH.\" This update can enhance our awareness of the need to improve not only HTN LVH but the other parts of the heart as well.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"247-254"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Insight into the Role of Vitamin D in the Stroke Risk: A Meta-Analysis of Stratified Data by 25(OH)D Levels. 维生素 D 对中风风险作用的新认识：按 25(OH)D 水平进行分层数据的 Meta 分析。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611331890241007112502

Maria Fusaro, Raffaele De Caterina, Giovanni Tripepi

{"title":"New Insight into the Role of Vitamin D in the Stroke Risk: A Meta-Analysis of Stratified Data by 25(OH)D Levels.","authors":"Maria Fusaro, Raffaele De Caterina, Giovanni Tripepi","doi":"10.2174/0115701611331890241007112502","DOIUrl":"10.2174/0115701611331890241007112502","url":null,"abstract":"Mendelian Randomization (MR) studies have emerged as a powerful tool for investigating causal relationships between modifiable risk factors and clinical outcomes, using genetic variants as instrumental variables. In the context of vitamin D research, MR is a promising approach to elucidate the effects of vitamin D on various health outcomes, including adverse cardiovascular events. However, the validity of MR analyses relies heavily on the strength of the genetic associations found. \"Weak instrument bias\", arising from instruments with low explanatory power for the exposure of interest, can lead to biased estimates and compromise causal inference. We have, herein, briefly reviewed the challenges posed by weak instrument bias in a large MR study on vitamin D [25(OH)D] and stroke, exploring implications for the study's validity and reliability of findings. We have then added an original meta-analysis stratified by 25(OH)D levels. By using aggregated data from a recent MR study, an original meta-analysis stratified by population mean levels of 25(OH)D has indicated that interventions based on vitamin D supplementations in population mean levels ranging from 50 to 70 nmol/L are likely to translate into a 13% reduction of stroke risk (pooled odds ratio=0.873, 95% CI: 0.764-0.997, p-value=0.04). MR studies are a valuable approach for discerning causal relationships between exposures, such as vitamin D, and health outcomes. However, the effectiveness of MR analyses depends on the robustness of the genetic instruments employed. By recognizing and addressing weak instrument bias in MR studies of vitamin D, researchers can enhance the credibility and utility of causal inference in understanding the health effects of this essential nutrient. A metaanalysis stratified by population mean levels of 25(OH)D has revealed the potential benefits of targeted interventions with vitamin D supplementations for stroke.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"67-72"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Promising Adventitia in Atherosclerosis. 动脉粥样硬化中的有希望的血管内膜。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611306375241211084246

Maolin Qiao, Ruijing Zhang, Xuezhen Xuan, Sheng Yan, Honglin Dong

引用次数: 0

Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial. Sarpogrelate 对改善外周动脉疾病 (PAD) 患者和/或有 PAD 风险的患者症状的有效性和安全性：单臂、多中心、开放标签试验。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611285172241015074050

Jong Chul Won, Tae-Jin Song, Jae Hyoung Park, Hee-Tae Kim, Kyong Hoon Lee, Keun Yong Park, Ho-Seung Jeong, Ung Jeon, Kyung Wan Min, Soo Lim

{"title":"Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial.","authors":"Jong Chul Won, Tae-Jin Song, Jae Hyoung Park, Hee-Tae Kim, Kyong Hoon Lee, Keun Yong Park, Ho-Seung Jeong, Ung Jeon, Kyung Wan Min, Soo Lim","doi":"10.2174/0115701611285172241015074050","DOIUrl":"10.2174/0115701611285172241015074050","url":null,"abstract":"Aims: To assess the efficacy and safety of sarpogrelate (300 mg) for symptom improvement in patients having peripheral arterial disease (PAD) and/or being at risk of PAD in clinical practice using the Peripheral Artery Questionnaire (PAQ).Background: Symptomatic changes with antiplatelets in patients with PAD are limited.Objective: To determine the effect and safety of sarpogrelate on the PAQ at 24 weeks from baseline.Methods: A total of 1003 patients having PAD and/or being at risk of PAD from 17 tertiary hospitals in South Korea who were treated with sarpogrelate, were enrolled in this study. PAQs were collected at baseline and at 12 and 24 weeks, together with physical examination and vital signs measurements. Lifestyle pattern was also investigated.Results: The average PAQ Summary Score in the efficacy evaluation analysis group significantly improved from 62.9 ± 23.7 at baseline to 68.9 ± 21.7 at 24 weeks (P<0.0001). Physical limitation items significantly improved from 69.5 ± 30.0 at baseline to 72.9 ± 28.3 after 24 weeks (P=0.0011). Symptom stability also significantly improved from 52.1 ± 21.6 at baseline to 63.6 ± 22.9 after 24 weeks (P<0.0001). Symptoms, treatment satisfaction, quality of life, and social limitation domains all improved after treatment. A total of 201 patients reported adverse events (20.0%), not directly associated with treatment.Conclusion: Treatment with 300 mg (orally) of sarpogrelate demonstrated statistically significant improvements in all domains and for the summary score of the PAQ at 24 weeks, it gave good results in terms of safety. Sarpogrelate may be helpful in reducing symptoms related to PAD.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"45-56"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful? 代谢功能障碍相关性脂肪性肝炎与心血管疾病的预防：Resmetirom 有用吗？

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611340703240809044916

Sanja Borozan, Snezana Vujosevic, Dimitri P Mikhailidis, Emir Muzurovic

引用次数: 0

Response to the Letter to the Editor: Rare Endocrine Disorders and Peripheral Arterial Disease. 对致编辑的信的回应：罕见的内分泌紊乱和外周动脉疾病。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611372375241125111238

Mojca Jensterle, Ales Blinc, Dimitri P Mikhailidis, Panagiotis Anagnostis, Gerit-Holger Schernthaner, Pier Luigi Antignani, Katica Bajuk Studen, Miso Sabovic, Pavel Poredos

引用次数: 0

Prognostic Value of Serum TMAO Measurement in Patients with STEMI: A Systematic Literature Review. STEMI患者血清TMAO测定的预后价值：系统文献综述。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611318147241118082012

Georgios Vakadaris, Theofanis Korovesis, Charalampos Balomenakis, Andreas S Papazoglou, Stavros P Papadakos, Ioannis Karniadakis, Dimitrios V Moysidis, Konstantinos Arvanitakis, Georgios Germanidis, Emmanouil S Brilakis, Anastasios Milkas

{"title":"Prognostic Value of Serum TMAO Measurement in Patients with STEMI: A Systematic Literature Review.","authors":"Georgios Vakadaris, Theofanis Korovesis, Charalampos Balomenakis, Andreas S Papazoglou, Stavros P Papadakos, Ioannis Karniadakis, Dimitrios V Moysidis, Konstantinos Arvanitakis, Georgios Germanidis, Emmanouil S Brilakis, Anastasios Milkas","doi":"10.2174/0115701611318147241118082012","DOIUrl":"10.2174/0115701611318147241118082012","url":null,"abstract":"Background: Gut microbiota-derived metabolite Trimethylamine-N-oxide (TMAO) is increasingly recognized as a potential novel prognostic biomarker for cardiovascular disease. Our research work aimed to investigate the potential utility of TMAO measurement in patients with STelevation Myocardial Infarction (STEMI).Methods: We performed a systematic literature search in PubMed from inception to the 1st of February 2024 to identify all studies examining the association between plasma TMAO levels and disease complexity or clinical outcomes in STEMI patients.Results: A total of eight prospective cohort studies were included, encompassing a total of 2,378 STEMI patients. Three of the studies provided only in-hospital evidence (i.e., increased odds for more severe coronary artery disease, plaque rupture, and plaque healing in patients with increased TMAO levels). Four studies examined the long-term prognostic value of TMAO after 10-12 months of follow-up post-STEMI (i.e., increased risk of adverse cardiovascular events in patients with increased TMAO levels), while one study provided data for both in-hospital and mid-term prognosis, indicating that 4-months after STEMI patients with greater TMAO elevation had larger infarct size.Conclusion: Higher TMAO levels were associated with a greater prevalence of high-risk coronary plaque characteristics and worse in-hospital and follow-up outcomes in STEMI patients. Further study is needed on whether modulating the diet-dependent TMAO levels could improve clinical outcomes in these patients.Registration number: [(OSF): https://doi.org/10.17605/OSF.IO/WNG8V].","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"196-203"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Energy Metabolism Dysregulation in Myocardial Infarction: An Integrative Analysis of Ischemic Cardiomyopathy. 心肌梗死中的能量代谢失调：缺血性心肌病的综合分析》。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611289159240724114844

Zongtao Wang, Zhixin Xie, Tudi Li, Rong Chen, Zhihuan Zeng, Jun Guo

{"title":"Energy Metabolism Dysregulation in Myocardial Infarction: An Integrative Analysis of Ischemic Cardiomyopathy.","authors":"Zongtao Wang, Zhixin Xie, Tudi Li, Rong Chen, Zhihuan Zeng, Jun Guo","doi":"10.2174/0115701611289159240724114844","DOIUrl":"10.2174/0115701611289159240724114844","url":null,"abstract":"Background: Myocardial metabolism is closely related to functional changes after myocardial infarction (MI).Objective: This study aimed to present an integrative examination of human ischemic cardiomyopathy.Methods: We used both GSE121893 single-cell suspension sequencing and GSE19303 transcription microarray data sets from the GEO database, along with a murine MI model for full-spectrum metabolite detection. Through a systematic investigation that involved differential metabolite identification and functional enrichment analysis, we shed light on the pivotal role of energy metabolism dysregulation in the progression of MI.Results: Our findings revealed an association between the core regulatory genes CDKN1A, FOS, ITGB4, and MAP2K1 and the underlying pathophysiology of the disease. These genes are identified as critical elements in the complex landscape of myocardial ischemic disorder, highlighting novel insights into therapeutic targets and the intricate biological mechanisms involved.Conclusion: This analysis provides a framework for future research on the metabolic alterations associated with MI.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"57-66"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence for the Interplay between Inflammation and Clotting System in the Pathogenetic Chain of Pulmonary Embolism: A Potential Therapeutic Target to Prevent Multi-organ Failure and Residual Thrombotic Risk. 肺栓塞发病链中炎症和凝血系统相互作用的证据：预防多器官衰竭和残余血栓风险的潜在治疗靶点。

IF 2.1 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611390778250321130817

Agata Buonacera, Benedetta Stancanelli, Debora Giarratana, Lorenzo Malatino

引用次数: 0

Rare Endocrine Disorders and Peripheral Arterial Disease. 罕见内分泌失调和外周动脉疾病。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611357349240925071626

Vasileios Papaioannou, Paraskevi Tsiantoula

引用次数: 0